Predictive value of tumor microenvironment PET/CT for aggressive lymphoma
Official title: The Predictive Value of Tumor Microenvironment PET/CT Imaging for Treatment Response and Prognosis in Aggressive Lymphoma: A Multicenter Clinical Study
Run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT07657494 · Data updated 2026-11-12
This study tests whether imaging of the tumor microenvironment can predict how patients with aggressive lymphoma will respond to treatment and what their prognosis might be.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 94 (estimated) |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Beijing, Chao Yang) |
| Status | Recruiting |
| Started | July 11, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT07657494 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with histologically confirmed aggressive lymphoma and moderate to high FDG uptake on baseline PET/CT who are suitable for imaging-based evaluation and can complete follow-up.
✕Probably not a fit
Patients with low FDG uptake, rapidly progressive disease, or contraindications to imaging procedures may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter study uses specialized PET/CT imaging to visualize components of the tumor microenvironment in aggressive lymphoma. Patients will receive FAPI PET/CT to assess fibroblast activation protein and, for selected immunotherapy candidates, Grazytracer PET/CT to gauge granzyme B activity. The goal is to develop imaging-based criteria and combined clinical-pathological-imaging models that predict treatment response, prognosis, and how tumor heterogeneity relates to relapse or refractoriness. The study will also explore the relationship between imaging findings and clinical outcomes to refine patient selection and monitoring. Eligible participants will have histologically confirmed aggressive lymphoma and adequate baseline imaging for evaluation.
Why it matters
Potential benefit: If successful, patients could receive more accurate predictions of treatment response and prognosis, guiding personalized therapy choices.
How similar studies have gone: Previous work has shown that tumor microenvironment imaging can provide prognostic information in some cancers, but this exact approach in aggressive lymphoma is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed aggressive lymphoma. * Baseline PET/CT showing moderate to high FDG uptake in lymphoma lesions. * No previous history of malignant tumors. * No significant cardiac, hepatic, or renal dysfunction. * Expected survival of at least 6 months and ability to complete follow-up. Exclusion Criteria: * Low FDG uptake on baseline PET/CT. * Lymphoma lesions have been surgically removed, with no positive lesions available for evaluation. * Active or uncontrolled chronic inflammation or infection. * Uncontrolled diabetes mellitus. * Incomplete clinical data or loss to follow-up. * Refusal to sign the informed consent form. * Inability to lie supine for 30 minutes.
Where it's running
-
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Chao Yang, China Recruiting
Study contacts
- Study coordinator: Xin Liu, M.D.
- Email: liux0077@163.com
- Phone: 15621479631
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Early palliative care for patients with multiple myeloma and aggressive lymphoma
This study is testing if early palliative care can improve the quality of life and comfort for people with multiple myeloma and aggressive lymphoma while they receive their usual cancer treatment.
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer
This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.
-
Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer
This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.
-
Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread
This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.
-
Three-dimensional lattice radiotherapy with PD-1/PD-L1 inhibitors for advanced solid tumors
This study tests whether adding lattice radiotherapy to PD-1/PD-L1 inhibitors is safe and helps people with advanced solid tumors that have grown or spread.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.